<DOC>
	<DOCNO>NCT00439803</DOCNO>
	<brief_summary>AVX601 , bivalent alphavirus replicon vaccine express three CMV protein ( gB , pp65 IE1 ) candidate vaccine cytomegalovirus ( CMV ) . The objective Phase 1 study test safety vaccine immune response vaccine healthy volunteer previously infect CMV . Volunteers assign randomization receive either vaccine inactive substance ( placebo ) injection arm three occasion 6 month . The study last 12 month total 12 visit .</brief_summary>
	<brief_title>A Clinical Trial Alphavirus Replicon Vaccine Cytomegalovirus ( CMV )</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled Phase 1 study safety immunogenicity AVX601 vaccine two dosage level two route administration healthy volunteer conduct single research center . A total 40 participant enrol two group 20 participant . Within group , participant randomize receive active vaccine IM injection ( N = 8 ) SC injection ( N = 8 ) receive placebo IM injection ( N = 2 ) SC injection ( N = 2 ) . Each participant receive total six injection vaccine placebo , two visit Weeks 0 , 8 24 , administer study nurse outpatient setting , follow 12 month first immunization . Safety data include local systemic reactogenicity dose vaccine , collect systematic format use subject memory aid standard grade scale , specific safety laboratory parameter general AEs . Immunogenicity data obtain collect blood define time point immunization separate serum ( measurement antibody CMV ELISA neutralization assay vaccine vector VRP neutralization assay ) peripheral blood mononuclear cell ( PMBC ) ( measurement cellular immune response CMV peptide ) .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>1 . Between 18 45 year age , inclusive 2 . Good general health without significant physical examination finding clinically significant abnormal laboratory result 3 . Available participate entire study period approximately 12 month 4 . For woman childbearing potential , negative urine pregnancy test screen immunization , agreement consistently use contraception 28 day prior enrollment last protocol visit , sexual activity could lead pregnancy 5 . Acceptable laboratory parameter : negative CMV serology hemoglobin ≥ 11.2 g/dL woman , ≥ 12.8 g/dL men white blood cell count 3,300 12,000 cells/mm3 platelet count 125,000 550,000/mm3 alanine aminotransferase ( ALT ) within normal range study laboratory serum creatinine within normal range study laboratory normal urine dipstick ( negative glucose , negative hemoglobin , negative trace protein ) negative hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) blood test negative HIV blood test 6 . Willingness blood store 10 year use additional assay evaluate immune response CMV alphavirus vector assay become available 7 . Willingness participate study evidence sign informed consent obtain screen 1 . Venous access deem inadequate phlebotomy demand study 2 . Women breast feed 3 . In female subject , positive urine pregnancy test screen day vaccine injection 4 . Receipt vaccine within 30 day prior enrollment 5 . Use investigational agent within 30 day prior enrollment 6 . Receipt immunoglobulin blood product within 60 day prior enrollment 7 . Use cytotoxic medication within 6 month prior enrollment 8 . Use systemic corticosteroid within 6 month prior enrollment ( except participant complete course prednisone , 20 mg per day 7 day , least 1 month prior enrollment eligible enrollment ) 9 . History serious adverse reaction vaccine , include anaphylaxis relate symptom hive , respiratory difficulty , angioedema abdominal pain 10 . History immunodeficiency autoimmune disease 11 . History diabetes mellitus 12 . History splenectomy 13 . History malignancy within last 3 year ( except participant diagnosis basal cell carcinoma skin eligible enrollment ) 14 . Psychiatric condition may interfere ability comply protocol requirement . Specifically excluded person history psychosis within past 3 year history suicidal attempt gesture within past 3 year . 15 . History medical , occupational family problem result alcohol illicit drug use past 12 month 16 . Any condition lead investigator believe participant comply protocol requirement may place participant unacceptable risk participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>CMV</keyword>
	<keyword>cytomegalovirus</keyword>
	<keyword>Alphavirus</keyword>
</DOC>